Dabigatran - Revision history

Zeki: /* Route of Administration */

2024-07-08T06:55:02Z

Route of Administration

← Older revision		Revision as of 02:55, 8 July 2024
Line 24:		Line 24:
	Oral		Oral

	Dosages		==Dosages==
	*For atrial fibrillation: 150 mg twice daily		*For atrial fibrillation: 150 mg twice daily
	Renal dose based on eGFR:		Renal dose based on eGFR:

Zeki: /* Common Strengths of Dabigatran */

2024-07-08T06:33:14Z

Common Strengths of Dabigatran

← Older revision		Revision as of 02:33, 8 July 2024
Line 8:		Line 8:
	==Common Strengths of Dabigatran==		==Common Strengths of Dabigatran==
	Dabigatran are available in the following strengths:		Dabigatran are available in the following strengths:
	75 mg, 110 mg, and 150 mg capsules		*75 mg, 110 mg, and 150 mg capsules

	==Drug Trade Names of Dabigatran==		==Drug Trade Names of Dabigatran==

Zeki: /* Side Effects */

2024-07-08T04:54:47Z

Side Effects

← Older revision		Revision as of 00:54, 8 July 2024
Line 48:		Line 48:
	\|-		\|-
	\| Minor bleeding		\| Minor bleeding
			\|-
	\| rowspan="4" \| '''Uncommon		\| rowspan="4" \| '''Uncommon
	\| Nausea, vomiting		\| Nausea, vomiting

Zeki at 04:02, 8 July 2024

2024-07-08T04:02:15Z

← Older revision		Revision as of 00:02, 8 July 2024
Line 6:		Line 6:

	'''Dabigatran (PRADAXA)'''（中文：[[達比加群]]）		'''Dabigatran (PRADAXA)'''（中文：[[達比加群]]）
			==Common Strengths of Dabigatran==
			Dabigatran are available in the following strengths:
			75 mg, 110 mg, and 150 mg capsules

			==Drug Trade Names of Dabigatran==
			Pradaxa

			==Drug Usage==
			*Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
			*Treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE)
			*Prevention of blood clots after hip or knee replacement surgery

			==Mechanism of Action==
			Directly inhibits thrombin, preventing blood clot formation

			==Route of Administration==
			Oral

			Dosages
			*For atrial fibrillation: 150 mg twice daily
			Renal dose based on eGFR:
			*eGFR >50 mL/min: No dosage adjustment required, standard dose of 150 mg twice daily
			*eGFR 30-50 mL/min:
			**75 mg twice daily for stroke prevention in atrial fibrillation
			**150 mg twice daily for treatment of DVT/PE, but use with caution
			*eGFR 15-30 mL/min: 75 mg twice daily for stroke prevention in atrial fibrillation

			==Side Effects==
			{\| class="wikitable"
			!style="text-align: left"\| Frequency
			!Adverse reactions
			\|-
			\| rowspan="5" \| '''Common
			\| Indigestion
			\|-
			\| Heartburn
			\|-
			\| Abdominal pain
			\|-
			\| Diarrhea
			\|-
			\| Minor bleeding
			\| rowspan="4" \| '''Uncommon
			\| Nausea, vomiting
			\|-
			\| Severe heartburn
			\|-
			\| Bleeding
			\|-
			\| Intracranial hemorrhage
			\|}

			==Pharmacokinetics==
			*Absorption
			**Peak plasma time 1 - 2 hours
			*Metabolism
			**Converted to active form dabigatran
			*Elimination
			**Primarily renal (80%)
			*Half-life
			**12 to 17 hours
			*Drug duration
			**12 to 17 hours

			==Drug Precautions==
			'''Pregnancy

			Not recommended

			'''Breastfeeding

			Not recommended

			'''Children and Elderly
			*Children: Safety and efficacy not established
			*Elderly: Increased risk of bleeding

			'''Monitoring Requirements

			Renal function, signs of bleeding

			'''Drug interactions

			P-gp inhibitors, anticoagulants, NSAIDs, antiplatelet drugs

			'''Caution
			*Use with caution in the elderly and in patients with low body weight
			*Use with caution in patients with bleeding disorders, gastritis, and oesophageal reflux

			==FAQ==
			'''How Should I Take the Tablet?

			Swallow capsules whole with water, with or without food. Do not open, break, or chew the capsules

			'''What Should I Avoid While Taking?

			Activities that increase the risk of bleeding or injury

			'''What Happens if I Miss a Dose?

			Take as soon as remembered if more than 6 hours until the next dose. If less than 6 hours, skip the missed dose and take the next scheduled dose.

Zeki at 03:15, 8 July 2024

2024-07-08T03:15:04Z

← Older revision		Revision as of 23:15, 7 July 2024
Line 1:		Line 1:
	[[Category: Drugs]][[Category: Direct Thrombin Inhibitor]]		[[Category: Drugs]][[Category: Direct Thrombin Inhibitor]]

	[[:Category: A Drug \| '''Anticoagulant Drug''']]		[[:Category: Anticoagulant Drug \| '''Anticoagulant Drug''']]

	'''Drug class: [[:Category: Direct Thrombin Inhibitor \| Direct Thrombin Inhibitor]]		'''Drug class: [[:Category: Direct Thrombin Inhibitor \| Direct Thrombin Inhibitor]]

	'''Dabigatran (PRADAXA)'''（中文：[[達比加群]]）		'''Dabigatran (PRADAXA)'''（中文：[[達比加群]]）

Zeki: Created page with "Category: DrugsCategory: Direct Thrombin Inhibitor '''Anticoagulant Drug''' '''Drug class: :Category: Direct Thrombin Inhibitor | Direct Th..."

2024-07-08T03:13:04Z

Created page with "Category: Drugs Category: Direct Thrombin Inhibitor '''Anticoagulant Drug''' '''Drug class: :Category: Direct Thrombin Inhibitor | Direct Th..."

New page

[[Category: Drugs]][[Category: Direct Thrombin Inhibitor]]

[[:Category: A Drug | '''Anticoagulant Drug''']]

'''Drug class: [[:Category: Direct Thrombin Inhibitor | Direct Thrombin Inhibitor]]

'''Dabigatran (PRADAXA)'''（中文：[[達比加群]]）